论文部分内容阅读
小细胞肺癌约占全部肺癌20%。近五年来研究的重点放在发现更完善的联合用药方案上,以提高完全缓解率,改善生存率。业已证明,许多抗癌药单用或联合用药对小细胞肺癌有效,其中足叶乙甙(Etoposide)可能是最有希望的一种。美国和欧洲的经验表明单用鬼臼脂素(Prodophllotoxin)的缓解率在20～51%。顺铂对小细胞肺癌的疗效较差,缓解率在0～12%之间。联合使用足叶乙甙和顺铂对P388白血病和B16恶性黑色素瘤显示抗肿瘤协同作用。Sierocki等用足叶乙甙加顺铂初治小细胞肺癌取得显著疗效(缓解率95%)。作者研究了该联合方案对常规治疗后复发或进展的小细胞肺癌的疗效。材料和方法:30例经组织学证实的晚期小细胞肺
Small cell lung cancer accounts for about 20% of all lung cancers. In the past five years, research has focused on finding more comprehensive drug combinations to increase the rate of complete remission and improve survival. It has been demonstrated that many anticancer drugs are used alone or in combination to treat small cell lung cancer, of which Etoposide may be the most promising one. The experience in the United States and Europe shows that the remission rate of Prodophllotoxin alone is between 20 and 51%. Cisplatin is less effective against small cell lung cancer and the remission rate is between 0 and 12%. The combined use of etoposide and cisplatin showed synergistic antitumor effects on P388 leukemia and B16 malignant melanoma. Sierocki et al achieved significant efficacy in the early treatment of small cell lung cancer with Etoposide plus cisplatin (remission rate 95%). The authors studied the effect of this combination regimen on relapsed or advanced small cell lung cancer after conventional therapy. Materials and Methods: 30 cases of histologically proven advanced small cell lung